EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

NCT04516161 · clinicaltrials.gov ↗

COMPLETED

Status

1180

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)

Sponsor

Bayer